MBD1

Across TCGA pan-cancer cohorts, MBD1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MBD1 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MBD1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MBD1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where MBD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.911	0.584	.012	11	view →
PDAC	OS	Quartile	II,III,IV	0.749	0.414	.014	7	view →
GBM	OS	Tertile	All	0.623	0.268	.037	2	view →
HNSC	DFS	Median	IV	0.523	0.760	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MBD1–CCRCC (OS)

Open the CCRCC breakdown →